Latest news about Oxygenta Pharmaceutical
Oxygenta Pharmaceutical
51.50
+1.93(+3.89%)
Company Performance:
View Company Insights1D+3.89%
1M-5.23%
6M-15.99%
1Y-47.58%
5Y+136.35%
More news about Oxygenta Pharmaceutical
22Oct 25
Oxygenta Pharmaceutical Faces 7-Day Manufacturing License Suspension for Four Key Drugs
Oxygenta Pharmaceutical Limited, a subsidiary of Virupaksha Organics Limited, received a seven-day suspension order for its manufacturing license from the Drugs Control Administration (DCA), Telangana. The suspension, effective from October 21, 2025, affects the production of four drugs: Etoricoxib, Vildagliptin, Lacosamide, and Telmisartan. The company estimates a potential revenue loss of Rs. 20.00 lakhs during this period. The suspension follows violations of rules under the Drugs and Cosmetics Act, 1940 and Rules 1945. The company's manufacturing license remains valid until April 23, 2028, but permission for the specified products is temporarily suspended.
16Oct 25
Oxygenta Pharmaceutical Receives BSE Approval for Promoter Reclassification
Oxygenta Pharmaceutical Limited has received approval from BSE Limited to reclassify four individuals from 'Promoter/Promoter Group' to 'Public' category. The approval, granted on October 16, 2025, follows the company's application on August 29, 2025. The reclassification involves Sai Sudhakar Vankineni, Snigdha Vankineni, Sumanth Simha Vankineni, and Jhansi Rani Vankineni. Oxygenta must now seek shareholder approval, comply with SEBI regulations, and make necessary disclosures regarding this change in shareholding structure.
25Aug 25
Oxygenta Pharmaceutical Undergoes Major Leadership Shake-up and Promoter Reclassification
Oxygenta Pharmaceutical reported significant changes including the resignation of Managing Director and CFO Mr. Vankineni Sai Sudhakar and Independent Director Mr. Sanagari Kondal Reddy. The board approved reclassification of four promoter group shareholders to public shareholders. Board committees were restructured with new appointments. The company's Annual General Meeting for FY 2024-25 is scheduled for September 19, 2025, via video conferencing.
19Aug 25
Oxygenta Pharmaceutical: Four Promoters Seek Reclassification Amid Management Changes
Oxygenta Pharmaceutical Limited is undergoing significant changes in its ownership and management structure. Four promoters, holding a combined 2.55% equity, have requested reclassification from 'Promoter' to 'Public' category. Simultaneously, the company announced the resignations of Managing Director and CFO Vankineni Sai Sudhakar and Independent Director Sanagari Kondal Reddy, effective August 18, 2025. The company will comply with SEBI regulations for the reclassification process, with the promoters confirming their adherence to regulatory requirements.
18Aug 25
Oxygenta Pharmaceutical Announces Key Leadership Resignations Amid Ownership Change
Oxygenta Pharmaceutical Limited, a subsidiary of Virupaksha Organics Limited, announced significant leadership changes. Managing Director and CFO Vankineni Sai Sudhakar and Independent Director Sanagari Kondal Reddy have resigned, effective August 18, 2025. Both cited the change in ownership and management as the reason for their departures. The company, known for its ISO certifications, made the disclosure in compliance with SEBI regulations. Executive Director Balasubba Reddy Mamilla signed the regulatory filing.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,788.50
(-0.08%)
6,576.50
(+0.67%)
4,368.50
(+1.17%)
1,375.20
(-0.30%)
1,076.60
(-0.16%)
1,263.30
(-0.84%)
2,261.20
(+0.51%)
2,369.50
(+3.07%)
1,440.40
(+0.78%)
1,394.30
(+0.85%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
